PHARMACYTE BIOTECH, INC. Selling Expense
PHARMACYTE BIOTECH, INC. (PMCB) reported Selling Expense of $108.98 thousand for the 6-month period ending 2021-10-31, per its 10-Q filed 2021-12-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingExpense · last filed 2021-12-14
- 2021-10-31: Selling Expense 6 month $108.98K.
| Period end | Selling Expense 6 month |
|---|---|
| 2021-10-31 | $108.98K 10-Q · filed 2021-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |